BR112016025126A2 - formulação líquida compreendendo composto neutralizante de gm-csf - Google Patents
formulação líquida compreendendo composto neutralizante de gm-csfInfo
- Publication number
- BR112016025126A2 BR112016025126A2 BR112016025126A BR112016025126A BR112016025126A2 BR 112016025126 A2 BR112016025126 A2 BR 112016025126A2 BR 112016025126 A BR112016025126 A BR 112016025126A BR 112016025126 A BR112016025126 A BR 112016025126A BR 112016025126 A2 BR112016025126 A2 BR 112016025126A2
- Authority
- BR
- Brazil
- Prior art keywords
- neutralizing compound
- csf neutralizing
- disorders
- liquid formulation
- formulation
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003472 neutralizing effect Effects 0.000 title abstract 3
- 239000012669 liquid formulation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000008181 tonicity modifier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se a formulações aquosas que compreendem um composto neutralizante de gm-csf em concentrações de pelo menos cerca de 20 mg/ml, um modificador de tonicidade, um tampão e um ou mais tensoativos, aminoácidos, antioxidantes e/ou quelantes, em que a composição é estável. os ingredientes da formulação fornecem, de preferência, estabilidade ao composto neutralizante de gm-csf em vista de armazenamento a longo prazo. em um aspecto preferencial, a formulação serve para uso em terapia, de preferência, para uso no tratamento de distúrbios inflamatórios e autoimunes, de preferência, incluindo distúrbios alérgicos e psoríaticos, bem como distúrbios artríticos e asmáticos.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167405 | 2014-05-07 | ||
| EP14167405.1 | 2014-05-07 | ||
| US201461994319P | 2014-05-16 | 2014-05-16 | |
| US61/994,319 | 2014-05-16 | ||
| US201462043636P | 2014-08-29 | 2014-08-29 | |
| US62/043,636 | 2014-08-29 | ||
| PCT/EP2015/059709 WO2015169742A1 (en) | 2014-05-07 | 2015-05-04 | Liquid formulation comprising gm-csf neutralizing compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016025126A2 true BR112016025126A2 (pt) | 2018-02-20 |
| BR112016025126A8 BR112016025126A8 (pt) | 2022-08-09 |
| BR112016025126B1 BR112016025126B1 (pt) | 2024-02-15 |
Family
ID=50721582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016025126-1A BR112016025126B1 (pt) | 2014-05-07 | 2015-05-04 | Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11173208B2 (pt) |
| EP (1) | EP3139960B1 (pt) |
| JP (1) | JP6769879B2 (pt) |
| KR (1) | KR102385802B1 (pt) |
| CN (1) | CN106659785B (pt) |
| AR (1) | AR100268A1 (pt) |
| AU (1) | AU2015257798C1 (pt) |
| BR (1) | BR112016025126B1 (pt) |
| CA (1) | CA2946230A1 (pt) |
| EA (1) | EA201691883A1 (pt) |
| ES (1) | ES2974895T3 (pt) |
| MX (1) | MX2016014411A (pt) |
| PH (1) | PH12016502100A1 (pt) |
| TW (1) | TWI682788B (pt) |
| WO (1) | WO2015169742A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
| CN107167613B (zh) * | 2017-06-22 | 2018-10-02 | 深圳清华大学研究院 | 用于等离子体金芯片的蛋白点样缓冲液 |
| EA202190955A1 (ru) * | 2018-10-01 | 2021-08-17 | Эмджен Инк. | Способы снижения агрегации биспецифических антител |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| AU2020370372A1 (en) * | 2019-10-25 | 2022-05-12 | Amgen Inc. | Compositions and methods for minimizing protein loss at low protein concentrations |
| US20230406943A1 (en) * | 2020-12-04 | 2023-12-21 | CSL Innovation Pty Ltd | Methods for treating inflammatory skin conditions |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| EP4337257A1 (en) * | 2021-05-12 | 2024-03-20 | AnaptysBio, Inc. | Antibody composition |
| WO2024114735A1 (en) * | 2022-12-01 | 2024-06-06 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Liquid pharmaceutical formulation of anti-gm-csf antibody and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0158487B1 (en) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| PT2275119E (pt) * | 1995-07-27 | 2013-11-21 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| DE69909459T2 (de) | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
| US7511476B2 (en) * | 2005-01-04 | 2009-03-31 | Digisensors, Inc. | Electromagnetic sensor systems and methods of use thereof |
| CA2605402C (en) * | 2005-04-18 | 2017-05-23 | Micromet Ag | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| PL3620171T3 (pl) | 2005-05-18 | 2022-08-08 | Morphosys Ag | Przeciwciała anty-gm-csf i ich zastosowania |
| JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| AU2007213716C1 (en) | 2006-02-08 | 2015-05-07 | Eisai, Inc. | Antigenic GM-CSF peptides and antibodies to GM-CSF |
| ES2424468T3 (es) | 2006-03-27 | 2013-10-02 | Medimmune Limited | Miembro de unión para el receptor GM-CSF |
| EP1970384A1 (en) | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| AU2008269086B2 (en) * | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| SG176499A1 (en) | 2007-11-13 | 2011-12-29 | Evec Inc | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
| BRPI0911902A2 (pt) | 2008-04-28 | 2015-10-13 | Kalobios Pharmaceuticals Inc | anticorpos para fator estimulador de colônia granulocítica-macrofágica |
| US9393304B2 (en) * | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| AU2010338305A1 (en) | 2009-12-29 | 2012-05-24 | F. Hoffmann-La Roche Ag | Antibody formulation |
| CN104995210A (zh) * | 2012-09-20 | 2015-10-21 | 莫弗***股份公司 | 类风湿关节炎的治疗 |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
-
2015
- 2015-05-04 KR KR1020167031014A patent/KR102385802B1/ko active IP Right Grant
- 2015-05-04 CN CN201580037108.0A patent/CN106659785B/zh active Active
- 2015-05-04 EA EA201691883A patent/EA201691883A1/ru unknown
- 2015-05-04 EP EP15720968.5A patent/EP3139960B1/en active Active
- 2015-05-04 AU AU2015257798A patent/AU2015257798C1/en active Active
- 2015-05-04 BR BR112016025126-1A patent/BR112016025126B1/pt active IP Right Grant
- 2015-05-04 ES ES15720968T patent/ES2974895T3/es active Active
- 2015-05-04 MX MX2016014411A patent/MX2016014411A/es unknown
- 2015-05-04 WO PCT/EP2015/059709 patent/WO2015169742A1/en active Application Filing
- 2015-05-04 US US15/307,214 patent/US11173208B2/en active Active
- 2015-05-04 JP JP2016566811A patent/JP6769879B2/ja active Active
- 2015-05-04 AR ARP150101336A patent/AR100268A1/es not_active Application Discontinuation
- 2015-05-04 CA CA2946230A patent/CA2946230A1/en active Pending
- 2015-05-07 TW TW104114614A patent/TWI682788B/zh active
-
2016
- 2016-10-20 PH PH12016502100A patent/PH12016502100A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016025126A8 (pt) | 2022-08-09 |
| TWI682788B (zh) | 2020-01-21 |
| AU2015257798C1 (en) | 2020-10-22 |
| MX2016014411A (es) | 2017-04-06 |
| PH12016502100A1 (en) | 2017-02-06 |
| EP3139960B1 (en) | 2024-01-17 |
| JP6769879B2 (ja) | 2020-10-14 |
| AU2015257798A1 (en) | 2016-11-17 |
| TW201622702A (zh) | 2016-07-01 |
| CN106659785B (zh) | 2021-04-30 |
| KR20160149210A (ko) | 2016-12-27 |
| JP2017514868A (ja) | 2017-06-08 |
| WO2015169742A1 (en) | 2015-11-12 |
| US11173208B2 (en) | 2021-11-16 |
| ES2974895T3 (es) | 2024-07-02 |
| KR102385802B1 (ko) | 2022-04-13 |
| EP3139960A1 (en) | 2017-03-15 |
| AU2015257798B2 (en) | 2020-04-23 |
| BR112016025126B1 (pt) | 2024-02-15 |
| US20170252436A1 (en) | 2017-09-07 |
| CA2946230A1 (en) | 2015-11-12 |
| CN106659785A (zh) | 2017-05-10 |
| AR100268A1 (es) | 2016-09-21 |
| EA201691883A1 (ru) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016025126A2 (pt) | formulação líquida compreendendo composto neutralizante de gm-csf | |
| BR112015009259B8 (pt) | Composição aquosa compreendendo o composto de neutralização do gm-csf | |
| NI201900041A (es) | 1, 2, 4-triazolonas 2, 4, 5-trisustituidas | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| BR112015014034A2 (pt) | inibidores de irak e usos dos mesmos | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| MX2015017457A (es) | Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento de inflamacion. | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| CU20170086A7 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| BR112015013783A2 (pt) | quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses | |
| NI201900063A (es) | Amidas aromáticas de ácido carboxílico | |
| CR20160055A (es) | Composiciones tópicas para el tratamiento de sudoración excesiva y métodos para utilizar las mismas | |
| TR201903470T4 (tr) | Kişisel hijyen için formülasyon. | |
| CL2015003460A1 (es) | Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica | |
| BR112015030373A2 (pt) | formulação farmacêutica de agomelatina para uso oral, processo de fabricação de uma formulação farmacêutica para uso oral, e, formulação farmacêutica | |
| TH168550A (th) | สูตรผสมของเหลวซึ่งประกอบรวมด้วยสารประกอบลบล้างฤทธิ์ gm-csf | |
| BR112015019320A2 (pt) | formulação sólida agroquímica | |
| TH168566A (th) | สูตรผสมของเหลวที่ประกอบรวมด้วยสารประกอบนิวทรัลไลซิง gm-csf | |
| AR112530A1 (es) | Composiciones farmacéuticas de ajoeno o un análogo o derivado de éste y sus usos | |
| PL415341A1 (pl) | Olejek eukaliptusowy i aloes do stosowania w leczeniu i profilaktyce stanów zapalnych wywołanych przez nużeńce, zwłaszcza zapalenia brzegów powiek, kompozycja farmaceutyczna zawierająca olejek eukaliptusowy i/lub aloes oraz zastosowanie olejku eukaliptusowego i aloes oraz ich kompozycja do wytwarzania preparatu do stosowania w leczeniu i profilaktyce wymienionych stanów zapalnych | |
| PT110896A (pt) | Forma amorfa de trifenatato de vilanterol e processos para a preparação da mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2015, OBSERVADAS AS CONDICOES LEGAIS |